Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL)

European Journal of Haematology

Volumn 86, Issue 3, 2011, Pages 246-255

  Markovic, Olivera ^a   Marisavljevic, Dragomir ^a,b   Cemerikic, Vesna ^c   Perunicic, Maja ^d   Savic, Sasa ^e   Filipovic, Branka ^a   Mihaljevic, Biljana ^b,d  

^a University Medical Center Bezanijska Kosa   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Beo Lab   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e CLINICAL CENTER OF VOJVODINA   (Serbia)

Author keywords

Apoptosis; Bcl 2; C FLIP; Caspase 3; Diffuse large B cell lymphoma; Fas; Immunohistochemisty; Prognosis; Survivin; XIAP

Indexed keywords

CASPASE 3; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; SURVIVIN; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; VINCRISTINE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; YOUNG ADULT;

EID: 79951593824     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01567.x     Document Type: Article

References (44)

1. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387-93.
2. The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
3. Hans CP, Weisenburger D, Greiner CG, Gascoyne RD, Delabie J, Ott G. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
4. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
5. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B cell lymphoma. J Clin Oncol 2006;24:995-1007.
6. Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor trough c-Flip. Eur J Immunol 2000;30:155-63.
7. Hengartner M. The biochemistry of apoptosis. Nature 2000;407:770-6.
8. Irisarri M, Plumas J, Bonnefoix T, Jacob MC, Roucard C, Pasquier MA, Sotto JJ, Lajmanovich A. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkins lymphoma cell line. Leukemia 2000;14:2149-58.
9. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
10. Kitada S, Pederson IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002;21:3459-74.
11. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916-23.
12. Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol 2006;24:97-104.
13. Kojima Y, Tsurumi H, Goto N, et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol 2006;76:465-72.
14. Jaffe ES, Harris NL, Stein H, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.
15. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwolds meeting. J Clin Oncol 1989;7:1630-6.
16. Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-9.
17. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of bcl-2 expression in diffuse large B cell lymphoma. Leuk Lymphoma 2007;48:1102-9.
18. Shivakumar L, Armitage JO. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 2006;6:455-7.
19. Barrans SL, Carter J, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-43.
20. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009;82:364-72.
21. Donogue S, Baden H, Lauder I, Sobolewski S, Pringle JH. Immunohistochemical localization of caspase-3 correlates with clinical outcome in b-cell diffuse large-cell lymphoma. Cancer Res 1999;59:5386-91.
22. Saez AI, Saez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613-22.
23. Lajmanovich A, Irisarri M, Molens JP, Pasquier MA, Sotto JJ, Bensa JC. Impairment of death-inducing signaling complex formation in CD95-resistant human primary lymphoma C cells. Br J Haematol 2004;124:746-53.
24. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtipes. Clin Cancer Res 2006;12:3265-71.
25. Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, Ozkan M, Er O, Cetin M, Unal A. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol 2006;81:307-14.
26. Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N. Prognostic significance of CD95, p53 and bcl-2 expression in exrtanodal non-Hodgkin's lymphoma. Ann Hematol 2010;89:889-96.
27. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mohotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24:1994-2007.
28. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;8:917-21.
29. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-5.
30. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T. Expression of survivin and of antigen detected by novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 2005;55:324-30.
31. Schlette EJ, Medeiros L, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-8.
32. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hodgkin's lymphomas. Leuk Res 2008;32:243-50.
33. Mainou-Fowler T, Overman LM, Dignum H, Wood K, Crosier S, Angus B, Proctor SJ, Anderson JJ. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 2008;32:59-68.
34. Valente G, Manfroi F, Peracchio C, Nicotra G, Castino R, Nicosia G, Kerim S, Isidoro C. c-Flip expression correlates with tumor progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancies. Br J Haematol 2006;132:560-70.
35. Van Houdt IS, Muris JJ, Hesselink AT, et al. Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation. Histopathology 2007;51:778-84.
36. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-8.
37. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S, Peter ME, Yang X. c-FLIP(L) is a dual function regulator for caspase 8 activation and CD 95 mediates apoptosis. EMBO J 2002;21:3704-14.
38. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
39. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, Schoch C, Haferlach T, Ludwig WD, Wuchter C. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004;5:489-95.
40. Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007;13:6056-63.
41. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
42. Song MK, Chung JS, Shin DH, Seol ZM, Shin HJ, Choi ZJ, Cho GJ. Prognostic significance of the bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. Leuk Lymphoma 2009;50:54-61.
43. Shen LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
44. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, Zhan Q. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2010;49:3-12.